« Zurück
Home /
Ginsenoside Ro

Ginsenoside Ro

ArtNr	HY-N0607-5mg
Hersteller	MedChem Express
CAS-Nr.	34367-04-9
Menge	5 mg
Quantity options	10 mM/1 mL 10 mg 25 mg 50 mg 5 mg
Kategorie	Oncology Food Safety Hormones Neuroscience Neural Lineage Markers Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Bladder Cancer Breast Cancer
Typ	Inhibitors
Specific against	other
Purity	99.81
Formula	C48H76O19
Citations	[1]Kwon HW, et al. Inhibitory Effects of Cytosolic Ca<sup>2+</sup> Concentration by Ginsenoside Ro Are Dependent on Phosphorylation of IP3RI and Dephosphorylation of ERK in Human Platelets. Evid Based Complement Alternat Med. 2015;2015:764906. [2]Jung-HaeShin, et al. Inhibitory effects of thromboxane A2 generation by ginsenoside Ro due to attenuation of cytosolic phospholipase A2 phosphorylation and arachidonic acid release. J Ginseng Res. 9 Jan 2018. [3]Kim S, et al. Upregulation of heme oxygenase-1 by ginsenoside Ro attenuates lipopolysaccharide-induced inflammation in macrophage cells. J Ginseng Res. 2015 Oct;39(4):365-70. [4]Jiang Z, et al. The traditional Chinese medicine Achyranthes bidentata and our de novo conception of its metastatic chemoprevention: from phytochemistry to pharmacology. Sci Rep. 2017 Jun 20;7(1):3888.
Smiles	O=C([C@]1(CCC(C)(C)C2)[C@]2([H])C3=CC[C@@]4([H])[C@@](C)(CC[C@]5([H])[C@@]4(CC[C@H](O[C@@](O[C@H](C(O)=O)[C@@H](O)[C@@H]6O)([H])[C@@H]6O[C@]([C@@H]([C@@H](O)[C@@H]7O)O)([H])O[C@@H]7CO)C5(C)C)C)[C@]3(C)CC1)O[C@@H]([C@@H]([C@@H](O)[C@@H]8O)O)O[C@@H]8CO
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Polysciasaponin P3, Chikusetsusaponin 5, Chikusetsusaponin V
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Natural Products
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	Calcium Channel; Prostaglandin Receptor
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	957.11
Product Description	Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) exhibits a Ca2+-antagonistic antiplatelet effect with an IC50 of 155 ?μM. Ginsenoside Ro reduces the production of TXA2 more than it reduces the activities of COX-1 and TXAS.
Manufacturer - Research Area	Cardiovascular Disease; Endocrinology
Solubility	DMSO : 100 mg/mL (ultrasonic)
Manufacturer - Pathway	GPCR/G Protein; Membrane Transporter/Ion Channel; Neuronal Signaling
Isoform	Calcium Channel; TXA2/TP
Clinical information	No Development Reported

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkdatenblatt anfordern

HY-N0607-5mg-safety-datasheet.pdf